What You Should Know:
- Syapse, a real-world evidence company that informs cancer care, announced a partnership with Bayhealth – central and southern Delaware’s largest healthcare system.
- Bayhealth will leverage Syapse’ multi-source real-world data platform to bring the latest in cancer diagnostics and treatments to Delaware patients, so that they can receive evidence-based care and match to potentially life-saving clinical trial opportunities.
Bringing Data-Driven Approach to
Read More
Oncology Technology Solutions, Services Impacting Patients and Providers
Cedars-Sinai Cancer Launches ‘Molecular Twin’ Initiative for Precision Cancer Treatment
What You Should Know:
- Cedars-Sinai Cancer and Tempus, a provider of artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients' DNA, RNA, protein and other information to help identify the most effective approach to each individual's disease.
- By creating these "molecular twins," scientists can genetically classify cancer genes and proteins of particular tumors
Read More
Ontada, Merck Partner to Facilitate Real World Evidence Studies for Cancer Care
What You Should Know:
- Ontada, McKesson’s oncology and insights business, announced a strategic agreement with Merck, known as MSD outside the United States and Canada, that will facilitate the development of real-world research excellence and innovation. This agreement enables the two healthcare leaders to harness the power of real-world evidence (RWE) towards the common goal of improving patient outcomes and the quality of cancer care.
- Ontada and Merck’s combined experience and
Read More
U of Chicago Med & COTA to Address Racial Disparities in Cancer Using RWD
What You Should Know:
- COTA, Inc., an oncology real-world data and analytics company and the University of Chicago Medicine announced a research collaboration agreement to investigate racial disparities of care in multiple myeloma to better understand differences in the diagnosis, treatment patterns, and outcomes of patients with this type of cancer.
- Multiple myeloma is the second-most-common hematologic malignancy, with an estimated 34,920 new cases and 12,410 deaths expected to occur
Read More
PAVmed Launches Veris Health With Acquisition of Oncodisc –M&A
What You Should Know:
- PAVmed announced today their launch of digital health company, Veris Health, along with Veris' acquisition of Oncodisc.
- Oncodisc was created by James Mitchell, M.D. and Andrew Thoreson, M.D. and brings the first implantable vascular access port with biologic sensors and wireless communication, combined with an oncologist-designed remote digital healthcare platform to improve outcomes and optimize the delivery of cost-effective care
Read More
Komodo Health Launches Next-Gen AI to Accelerate Innovation and Close Gaps in Care
What You Should Know:
- Today, Komodo Health is capping off a month-long flurry of activity by announcing the launch of its Prism and Sentinel solutions — opening up access to its Healthcare Map to drive the next generation of AI innovation.
- Prism and Sentinel allows life sciences teams to tap into detailed patient behaviors and treatment patterns based on the real-world patient journeys of more than 325 million patients. The breakthrough software also allows life sciences teams to
Read More
PHINs: Addressing the Fundamental Flaws that Have Broken Healthcare
The fundamental problem with healthcare can be summed up in one sentence: We expect healthcare services that cater to our individual needs, yet the health care system operates under a one-size-fits-all, trial-and-error model. It is a model that results in missed diagnoses, protracted illnesses, and even premature death and wastes $935 billion annually.
The financial toll of this outmoded approach pales in comparison to the human toll. More than 128,000 people in the U.S. die each year
Read More
Cardinal Health and Deep Lens Collaborate for AI-based Oncology Clinical Trial Matching
What You Should Know:
- Today, Deep Lens and Cardinal Health announced a strategic collaboration that will integrate Deep Lens’ AI-based clinical trial matching solution, VIPER, into community-based oncology practices throughout the Cardinal network. VIPER will be a part of Cardinal Health’s new Navista advanced suite of technology solutions designed to help oncologists improve outcomes, provide high quality care at the best possible cost and select the right care plan at the onset of
Read More
To Advance Health Equity, Put Real-World Cancer Data to Work
Despite decades of scientific progress against cancer, access to treatment remains highly unequal. Some of the reasons — like institutional racism and poverty — are a reflection of our broader society. Other inequities may go unrecognized but are no less damaging. People with underlying health conditions, for example, may be excluded from clinical trials, preventing them from accessing leading-edge treatments and limiting the evidence available to guide their care.
With multiple drivers of
Read More
NeoGenomics Acquires Precision Oncology Platform Trapelo Health for $65M
What You Should Know:
- NeoGenomics, Inc., a provider of cancer-focused genetic testing services and global oncology contract research services announced it has reached an agreement to acquire precision oncology platform Trapelo Health for $65M. The agreement purchase price of $65 million, consists of $35 million in cash on hand and $30 million in NeoGenomics common stock and is expected to close in April 2021.
- Trapelo Health offers a first-of-its-kind, interoperable, decision-support
Read More
